[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"solar-lentigo\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:solar-lentigo":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,70],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100645197","a-clinical-study-to-evaluate-the-efficacy-in-improving-dark-spots-after-8-weeks-of-use-of-facial-sunscreens-in-adult-participants-100645197",false,"NCT07679945","A Clinical Study to Evaluate the Efficacy in Improving Dark Spots After 8 Weeks of Use of Facial Sunscreens in Adult Participants","A Monocentric and Open-Label Clinical Study to Evaluate the Efficacy in Improving Dark Spots After 8 Weeks of Use of Facial Sunscreens in Adult Research Participants","El Porto Ex-US","Inclusion Criteria:\n\n1. Able to understand and follow study instructions\n2. Fitzpatrick skin types I-VI\n3. Presence of facial hyperpigmentation, such as:\n\n   * Mild to moderate melasma, or\n   * Visible dark spots (e.g., solar lentigines or post-inflammatory hyperpigmentation)\n4. Willing to comply with study procedures and product use\n5. For subjects in applicable groups: willing to use assigned sunscreen product\n\nExclusion Criteria:\n\n1. Known sensitivity or allergy to cosmetic or skincare products\n2. Skin conditions or lesions in the study area that could interfere with evaluation (e.g., active dermatitis, infections, significant irritation, or extensive scarring)\n3. Use of medications or products that may interfere with study evaluations\n4. Recent cosmetic or dermatological procedures in the study area (e.g., chemical peels, laser treatments, invasive procedures)\n5. Excessive sun exposure or use of tanning beds immediately prior to or during the study\n6. Pregnancy or intention to become pregnant during the study\n7. Participation in another clinical study within a recent period\n8. Any condition or situation that, in the investigator's judgment, may interfere with study participation or evaluation of results",true,"ALL","18 Years",{"count":21,"type":22},152,"ESTIMATED","INTERVENTIONAL",[25],"NA","The study aims to evaluate the efficacy of a facial sunscreen under two experimental conditions-untinted and tinted-in improving facial spots (melasma and solar lentigines\u002Fpost-inflammatory hyperpigmentation) after 8 weeks of product use under normal conditions by adult participants.",[28,29,30],"Post-inflammatory Hyperpigmentation","Melasma","Solar Lentigo","RECRUITING","2026-06-25",{"date":34,"type":35},"2026-07-01","ACTUAL",{"date":37,"type":35},"2026-06-02",{"date":39,"type":22},"2026-09-25",{"name":41,"class":42},"Kenvue Brands LLC","INDUSTRY",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":17,"sex":18,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":4},"100625988","evaluation-of-efficacy-and-tolerabilty-of-melab3-serum-in-combination-of-35-glycolic-acid-peeling-compared-to-35-glycolic-acid-peeling-alone-in-various-hyperpigmentation-conditions-100625988","NCT07429786","Evaluation of Efficacy and Tolerabilty of MelaB3 Serum in Combination of 35% Glycolic Acid Peeling Compared to 35% Glycolic Acid Peeling Alone in Various Hyperpigmentation Conditions","Randomized Clinical Trial to Assess the Effectiveness and Tolerability of MELA B3 Serum in Combination With 35% Glycolic Acid Peel vs. 35% Glycolic Acid Peel for the Treatment of Various Hyperpigmentation Conditions (Melasma, Post-inflammatory Hyperpigmentation and Solar Lentigo) and Signs of Aging in a Population of Participants From the Autonomous City of Buenos Aires, Argentina.","Inclusion Criteria:\n\n1. Women and men\n2. From 30 to 70 years of age (inclusive)\n3. Good general health\n4. With any type of phototype\n5. Hyperpigmentation condition with average darkness \\> 3:\n\n   1. Epidermal or mixed melasma (determined by Wood's lamp examination at screening), mild to moderate melasma (IGA 1 or 2)\n   2. Post acne inflammatory hyperpigmentation (PIHP), mild to moderate (IGA 1 or 2) with no active acne and less than 10 inflammatory lesion on full face\n   3. Solar lentigo (SL) with a pigmentation score\\>5\n6. Willingness to protect oneself from the sun as much as possible for the duration of the study\n7. Willingness to avoid contraindicated products (irritants, other depigmenting agents)\n8. Signing of written informed consent\n\nExclusion Criteria:\n\n1. Pregnant, breastfeeding or with pregnancy plans.\n2. All contraindications for superficial peeling (for example, concomitant infectious processes or inflammatory processes that affect the skin barrier).\n3. Melasma with predominance of the pigmentary component at the dermis level, observed with Wood's light at the inclusion visit.\n4. Active acne with 10 or more inflammatory lesions.\n5. In the case of melasma, participants with recent change of contraception (less than 3 months) or less than 3 months since childbirth.\n6. Participant using irritating products (require a washout period of at least 2 weeks).\n7. Use of medications that may induce melasma, such as antiepileptics (requires a washout period of 1 month).\n8. Use of other products with depigmenting activity (requires a washout period of 1 month).\n9. Other facial dermatoses or known photosensitivity, or a pre-existing or latent dermatologic health condition and\u002For disease on the face (e.g., psoriasis, rosacea, acne, eczema, seborrheic dermatitis, severe excoriations) that, in the judgment of the investigator, are considered inappropriate for participation or may interfere with study results.\n10. Topical treatments applied to the face (requires a 2-week washout period).\n11. Scheduled facial procedures during the course of the study.\n12. Participants undergoing phototherapy (requires a 1-month washout period).\n13. Known hypersensitivity to study products.\n14. History of laser resurfacing procedures, intense pulsed light, facial radiofrequency, deep peeling, facial mesotherapy with tranexamic acid, botulinum toxin or dermal filler injections, or cosmetic procedures on the face within 6 months prior to the start of the study.\n15. Facial treatment with microdermabrasion within 6 weeks prior to study entry.\n16. Persons with visible tanning, scars, moles, excessive hair or other dermal conditions on the face that, in the judgment of the investigator, may influence the results of the study.\n17. History of skin cancer, immunosuppression or immunodeficiency disorders (including HIV infection or AIDS), or current use of immunosuppressive drugs.\n18. Uncontrolled disease such as asthma, diabetes, hypertension, hyperthyroidism or hypothyroidism. Persons with multiple health conditions may be excluded, even if controlled by diet or medication.\n19. Participation in another clinical trial within one week prior to entering this study.","30 Years","70 Years",{"count":54,"type":22},80,[25],"Randomized clinical trial to assess the effectiveness and tolerability of Mela B3 serum in combination with 35% glycolic acid peel vs. 35% glycolic acid peel for the treatment of various hyperpigmentation conditions (melasma, post-inflammatory hyperpigmentation and solar lentigo) and signs of aging in a population of participants from the Autonomous City of Buenos Aires, Argentina.",[58,29,30,59],"Hyperpigmentation","Peeling","NOT_YET_RECRUITING","2026-02-17",{"date":63,"type":35},"2026-02-24",{"date":65,"type":22},"2026-03-04",{"date":67,"type":22},"2026-06",{"name":69,"class":42},"Cosmetique Active International",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":17,"sex":78,"minAge":79,"maxAge":52,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":82,"briefSummary":83,"conditions":84,"keywords":85,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":43},"100611372","clinical-investigation-to-evaluate-the-efficacy-and-safety-of-epilady-prototype-device-followed-by-application-of-a-topical-formula-on-depigmentation-of-lentigo-spots-100611372","NCT07239726","CLINICAL INVESTIGATION TO EVALUATE THE EFFICACY AND SAFETY OF EPILADY PROTOTYPE DEVICE FOLLOWED BY APPLICATION OF A TOPICAL FORMULA ON DEPIGMENTATION OF LENTIGO SPOTS","CLINICAL INVESTIGATION TO EVALUATE THE EFFICACY AND SAFETY OF EPILADY PROTOTYPE DEVICE FOLLOWED BY APPLICATION OF A TOPICAL FORMULA ON DEPIGMENTATION OF LENTIGO SPOTS IN HEALTHY WOMEN PARTICIPANTS - STUDY UNDER DERMATOLOGICAL CONTROL","EPILADY","Inclusion Criteria:\n\n* Healthy female participants aged between 35 and 70 years old at the time of inclusion.\n* All Fitzpatrick skin phototypes (I to VI) are eligible; groups I-II and V-VI should include at least one participant per group.\n* Presence of at least two solar lentigo (dark spots) on each hand or forearm, with each spot measuring less than 100 mm x 100 mm as assessed by the investigator.\n* Participant has read, understood, and accepted the constraints of the clinical investigation.\n* Participant has provided written informed consent to participate in the clinical investigation.\n* Participant is able to understand the language used in the investigational site and comprehend the information provided.\n* Participants are cooperative and compliant, aware of the clinical investigation requirements and willing to adhere to the full duration of participation and follow-up visits, in line with the CIP requirements.\n* Women of childbearing potential must commit to using an effective contraceptive method throughout the clinical investigation period and for at least three months prior to the inclusion visit, with no changes during that time.\n\nExclusion Criteria:\n\n* • Participants with dry or sensitive skin, as assessed by the investigator.\n\n  * Participants who have used cosmetic products with exfoliating or astringent claims on the hands within 4 weeks prior to the baseline visit.\n  * Participants who have used any home-use or professional low-level laser therapy (LLLT) or have participated in clinical studies involving LLLT within the 6 months preceding the baseline visit\n  * History of light-induced seizures or chronic migraine disorders.\n  * History of photosensitivity or photoallergic reactions.\n  * Presence of underlying dermatological conditions on the hands\u002Fforearms that, in the opinion of the investigator, could interfere with the clinical investigation assessments.\n  * A family history of melanoma in first- or second-degree relatives (parents or grandparents).\n  * Presence of excessive moles, non-lentigo pigmented lesions, tattoos, scars, or irritated skin in the test area that could affect the validity of the investigation.\n  * History of surgical procedures involving the areas designated for treatment.\n  * Participants who have been exposed to or plan to be exposed to sunbathing or artificial UV sources (e.g., mountain sports, phototherapy, tanning salons) within 1 month before the clinical investigation start or during the clinical investigation period.\n  * Use of suntan or self-tanning products within the 2 weeks preceding the baseline visit.\n  * Change in cosmetic habits (e.g., moisturizers, skincare, shower gels) during the 2 weeks prior to baseline.\n  * Use of any medications, topical treatments, skincare products, or aesthetic procedures listed in the CIP without observing the required wash-out periods, or unwillingness\u002Finability to comply with those restrictions during the clinical investigation.\n  * Participant who cannot be contacted by telephone in case of emergency\n  * Participant in an exclusion period or participating in another biomedical research clinical investigation (self-reported)\n  * Intellectual\u002Fmental inability to follow clinical investigation instructions (if suspected) or incapacitation.\n  * Participants working for the contract research organization (CIDP) in charge of this clinical investigation.","FEMALE","35 Years",{"count":81,"type":22},44,[25],"To assess the efficacy of the Epilady investigational device, used with and without a topical depigmenting formula, in reducing the appearance of lentigo spots on the hands and forearms of healthy female participants over an 84-day period",[30],[86,87],"solar lentigo,","Laser treatment","2025-11-16",{"date":90,"type":35},"2025-11-20",{"date":92,"type":22},"2026-01-07",{"date":94,"type":22},"2026-05-08",{"name":69,"class":42}]